LKFT · Lakefront Biotherapeutics NV
$27.74
-0.41 (-1.46%)
At close · Jul 29
Market Cap
$1.84B
Shares
65.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.15
Open$28.22
Day$27.87–28.65
52W$26.42–37.78
Avg vol 30d149K
Short int2.3M · 3.5% float · 16.2d
Short vol83%
Last earningsDec 31, 2025
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−2%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
15%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−18%
trailing
YTD return
−14%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow
Distributing
18 of 90 funds reported for Jun 30 · net -54.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.55% of float · ▲ +3.8% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
90 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
28%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
15%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow
Distributing
18 of 90 funds reported for Jun 30 · net -54.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.55% of float · ▲ +3.8% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
90 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $26
Now $28 · 15%
52-wk high $38
vs 200-day avg -9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LKFT
this stock
Lakefront Biotherapeutics NV
|
$1.84B | -13.9% | — | — | 3.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LKFT | -3.0% | -4.5% | -17.8% | -6.1% | -13.9% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.0% | -4.5% | -25.2% | -5.3% | -22.6% |
Key facts
CIK
1421876
CUSIP
36315X101
13F (30d)
16 filings
14 filers
Visit website
Investor relations